Do you have the feeling that your project is not progressing as
as you would like it to?
Are you looking for an expert who has a lot of experience and is able to look at the problem from
a completely different perspective?
On my website you will find information about me:
Who I am, what I do and what experience I bring.
I work in a non-bureaucratic and solution-oriented way.
Then let's talk!
since 10/2021: Freelancer: @qmc-med.com
05/2005 – 01/2022: Direktor / Senior Vice President New Business at Desitin Arzneimittel GmbH (Hamburg): 17 years
Established a global licensing network and a professional liaison management with strategic partners in pharma, MedTech and biotech; Performed in- and out-licensing projects as well as a selection of new product development in full responsibility; Reached about 50% of current turnover with NewBizz projects; Created concepts for a long-term and strategic development of the company; Supervising in-house staff (up to 50 people incl. 15 academics)
07/2004 – 04/2005: Head of Business Development
at Haupt Pharma AG (Berlin): 1 year
Evaluated and implemented a new business segment; Strengthened internationalizing the group; Actively performed M&A projects; Searched and acquired new development projects; Managed strategic development projects
09/1988 – 03/2004: Several Positions incl. Member of the Board at Arzneimittelwerk Dresden (Dresden; AWD) & ASTA Medica AG (Frankfurt, following acquisition of AWD in 2000): 16 years
Member of a restructuring team with responsibility for a divestment program including private equity and strategic investors; Headed a division of 100 employees in R&D and Quality Management; Project management of a variety of NCEs, specialty products, generics, manufacturing transfer projects; Founded a department of Pharmacokinetics & Metabolism
Highly advanced expertise in therapeutic options in neurology, in rare diseases as well as in other indications;
International horizon with multi-cultural skills;
More than thirty years of professional experience in well-established and renowned specialty pharmaceutical enterprises;
Broad experience in development, project management, licensing, business case compilation, financial evaluation and negotiation of pharma deals;
Overseeing the complete worldwide landscape of new product opportunities in neurology and neighboring therapeutic indications with contacts to key opinion leaders and leading industry players around the world;
Additional business excellence in branded generics, new chemical entities, biologics, bacteriophages, repurposing/repositioning, MedTech, diagnostics, digital health as well as other beyond-the-pill technologies in neurology
2005 – today: In-licensing of more than 80 products;
Successful portfolio renewal by in-licensing CNS drugs and generating short-term revenues up to a “New Product Ratio” of 50 % of the total sales within 5 years (e.g. with Servier, France; Biocodex, France; Zogenix, USA; Neurim, Israel; Pozen, USA; Dr.Schär, Italy);
Network within digital health and Beyond-the-Pill technologies;
2006: Created a new Business Development Department;
2005: Established a new Drug Development Business Unit;
2003: Restructured a new company on a green field approach followed by the divestment negotiations with private equity and strategic investors;
2001 – 2004: In-licensing of proprietary and generic products (e.g. Merck, Germany; Astra Zeneca, Sweden);
2001 – 2004: Development of several modified release formulations for proprietary drugs in pain and epilepsy;
1993 – 1999: Project Management of an NCE co-development of ASTA Medica AG (Germany) & Wyeth-Ayerst Research (USA), global development of an anti-epileptic from drug lead definition until phase IIb of clinical testing (INN: Retigabine);
Project Management of three NCE projects (CNS) reaching first-dose-in-man as critical clinical milestone